Crizotinib, an FDA-approved small molecule inhibitor of the ALK, MET and ROS1 tyrosine kinases for advanced NSCLC [60–63], has shown satisfactory antitumor activity [64]. This evidence concerns the gene ALK and non-small cell lung carcinoma.